HK1251157A1 - 使用ACTRII配体陷阱治疗β-地中海贫血 - Google Patents

使用ACTRII配体陷阱治疗β-地中海贫血 Download PDF

Info

Publication number
HK1251157A1
HK1251157A1 HK18110608.3A HK18110608A HK1251157A1 HK 1251157 A1 HK1251157 A1 HK 1251157A1 HK 18110608 A HK18110608 A HK 18110608A HK 1251157 A1 HK1251157 A1 HK 1251157A1
Authority
HK
Hong Kong
Prior art keywords
thalassemia
beta
treatment
actrii ligand
ligand traps
Prior art date
Application number
HK18110608.3A
Other languages
English (en)
Chinese (zh)
Inventor
M 阿蒂 肯尼士
拉亚德姆 阿伯达拉曼恩
乔普拉 拉杰什
拉亞德姆 阿伯達拉曼恩
巴克斯托姆 杰伊
喬普拉 拉傑什
巴克斯托姆 傑伊
Original Assignee
细胞基因公司
細胞基因公司
埃克赛勒隆制药公司
埃克賽勒隆製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 细胞基因公司, 細胞基因公司, 埃克赛勒隆制药公司, 埃克賽勒隆製藥公司 filed Critical 细胞基因公司
Publication of HK1251157A1 publication Critical patent/HK1251157A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18110608.3A 2015-05-13 2016-05-12 使用ACTRII配体陷阱治疗β-地中海贫血 HK1251157A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562161136P 2015-05-13 2015-05-13
US62/161,136 2015-05-13
US201562173836P 2015-06-10 2015-06-10
US62/173,836 2015-06-10
US201562243457P 2015-10-19 2015-10-19
US62/243,457 2015-10-19
PCT/US2016/031999 WO2016183280A1 (en) 2015-05-13 2016-05-12 Treatment of beta-thalassemia using actrii ligand traps

Publications (1)

Publication Number Publication Date
HK1251157A1 true HK1251157A1 (zh) 2019-01-25

Family

ID=57248528

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110608.3A HK1251157A1 (zh) 2015-05-13 2016-05-12 使用ACTRII配体陷阱治疗β-地中海贫血

Country Status (15)

Country Link
US (1) US20180125928A1 (https=)
EP (1) EP3294320A4 (https=)
JP (2) JP6976859B2 (https=)
KR (1) KR102640198B1 (https=)
CN (1) CN107847562A (https=)
AU (2) AU2016261913B2 (https=)
CA (1) CA2985777A1 (https=)
HK (1) HK1251157A1 (https=)
IL (2) IL284686B2 (https=)
JO (1) JOP20160092B1 (https=)
MY (1) MY189601A (https=)
PH (1) PH12017502079A1 (https=)
TN (1) TN2017000468A1 (https=)
TW (2) TWI814187B (https=)
WO (1) WO2016183280A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
CN108350057A (zh) 2015-05-20 2018-07-31 细胞基因公司 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3380121B1 (en) 2015-11-23 2023-12-20 Acceleron Pharma Inc. Actrii antagonist for use in treating eye disorders
DK3496739T3 (da) 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
MA45811A (fr) 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.
NZ754161A (en) 2016-11-10 2025-11-28 Keros Therapeutics Inc Activin receptor type iia variants and methods of use thereof
PL3638243T3 (pl) * 2017-06-14 2025-02-10 Celgene Corporation Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
WO2019213016A1 (en) 2018-04-30 2019-11-07 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
JP7663502B2 (ja) * 2018-10-31 2025-04-16 セルジーン コーポレイション 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療
EP3999059A1 (en) 2019-07-19 2022-05-25 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (tdt)
CN112924684B (zh) * 2019-12-05 2022-07-29 中国科学院大连化学物理研究所 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒
WO2021189019A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
US20230181690A1 (en) * 2020-04-13 2023-06-15 Celgene Corporation Methods for treating anemia using an actriib ligand trap and fedratinib
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
US20230270821A1 (en) * 2020-11-06 2023-08-31 Acceleron Pharma Inc. Formulations comprising actrii polypeptide variants
WO2022150590A1 (en) * 2021-01-08 2022-07-14 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
MX2023008515A (es) 2021-01-20 2023-07-27 Vifor Int Ag Inhibidores de ferroportina para su uso en el tratamiento de sindromes mielodisplasicos (smd).
KR20260028017A (ko) 2023-06-26 2026-03-03 비포르 (인터내셔날) 아게 유전성 혈색소침착증(hh)의 치료에 사용하기 위한 페로포틴-저해제
WO2025122830A1 (en) * 2023-12-08 2025-06-12 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247A (en) * 1845-11-01 Jordan l
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
CN102131822A (zh) * 2008-06-26 2011-07-20 阿塞勒隆制药公司 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
TW201803586A (zh) * 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
EP3202459B1 (en) * 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
KR20140084211A (ko) * 2011-10-17 2014-07-04 악셀레론 파마 인코포레이티드 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물
MX2014011836A (es) * 2012-03-30 2015-03-09 Shire Human Genetic Therapies Administracion subcutanea de iduronato-2-sulfatasa.
CN104968801B (zh) * 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
HK1214504A1 (zh) * 2012-10-24 2016-07-29 细胞基因公司 用於治療貧血的方法
CN109554350B (zh) * 2012-11-27 2022-09-23 儿童医疗中心有限公司 用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件

Also Published As

Publication number Publication date
IL255527A (en) 2018-01-31
TW201709927A (zh) 2017-03-16
CN107847562A (zh) 2018-03-27
EP3294320A4 (en) 2018-12-26
AU2021258087A1 (en) 2021-11-25
IL255527B (en) 2021-07-29
JP6976859B2 (ja) 2021-12-08
TN2017000468A1 (en) 2019-04-12
WO2016183280A1 (en) 2016-11-17
AU2016261913A1 (en) 2017-11-30
IL284686B2 (en) 2023-05-01
NZ737043A (en) 2025-02-28
JP2021191755A (ja) 2021-12-16
MY189601A (en) 2022-02-18
CA2985777A1 (en) 2016-11-17
AU2021258087B2 (en) 2023-04-27
TW202231294A (zh) 2022-08-16
IL284686B (en) 2023-01-01
TWI814187B (zh) 2023-09-01
KR102640198B1 (ko) 2024-02-23
TWI762444B (zh) 2022-05-01
US20180125928A1 (en) 2018-05-10
AU2016261913B2 (en) 2021-08-12
PH12017502079A1 (en) 2018-06-11
EP3294320A1 (en) 2018-03-21
KR20180006437A (ko) 2018-01-17
JOP20160092B1 (ar) 2023-03-28
IL284686A (en) 2021-08-31
JP2018520094A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
HK1251157A1 (zh) 使用ACTRII配体陷阱治疗β-地中海贫血
WO2018089669A3 (en) Immunotherapeutic tumor treatment method
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
HK1247093A1 (zh) 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法
EP3808367A3 (en) Targeting aneurysm disease by modulating phagocytosis pathways
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
HK1217092A1 (zh) 治疗性化合物及其用途
MX2019012285A (es) Metodos de tratamiento de encefalopatias del desarrollo.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
TN2015000356A1 (en) Bicyclic compounds
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
WO2016004413A3 (en) Gls1 inhibitors for treating disease
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
EA201991269A1 (ru) Профилактический агент, агент, подавляющий начало заболевания, или терапевтический агент для прогрессирующих иммунных демиелинизирующих заболеваний
WO2016164719A3 (en) Methods used to treat cancer
AR104621A1 (es) TRATAMIENTO DE LA b-TALASEMIA POR EL USO DE TRAMPAS DE LIGANDO ActRII
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
EA201892675A1 (ru) Фармацевтическая композиция, содержащая этеплирсен
HK1233927A1 (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use